
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics is a commercial-stage medical diagnostics technology company with a positive outlook due to its potential for Medicare coverage for its EsoGuard test, a high-value market opportunity for its EsoGuard and EsoCheck products, and its recent regulatory and commercial successes, such as its Laboratory Benefit Manager (LBM) contract with Concert and its positive coverage from Highmark BCBS. Additionally, the company has enough cash on hand to sustain operations for the next few years and is making progress in expanding its sales force and securing contracts with commercial health plans.
Bears say
Lucid Diagnostics is yet to generate significant revenue despite its Q2'26 revenue growth of 27% YoY. Its flagship product, EsoGuard, which has FDA breakthrough device designation and has been commercialized as an LDT, has potential to be a revolutionary solution for the large unmet need in preventing esophageal adenocarcinoma. However, there are concerns about the company's cash usage, competition, and lack of Medicare coverage, which, if not addressed, could hinder the company's growth potential.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares